Ariosa Diagnostics, Inc.
Ariosa had a few dozen people in 2010 when it raised $12.5M and began relying on StemExpress as a supplier and then clinical trial partner for its development of the Harmony™ Prenatal Test. The successful development of that test lead to Roche acquiring Ariosa for $625M in January of 2015 (Press Release).
Verinata Health, Inc.
Verinata began utilizing StemExpress in 2011 as a provider of research and clinical grade blood samples used in the development of their non-invasive prenatal tests (NIPTs) for the early identification of fetal chromosomal abnormalities. Just two years later in 2013, Illumina acquired Verinata for $350M plus up to an additional $100M in payments through 2015 (Press Release).
Grail has become a leader in advancing the research into the early detection of cancers through analyzing cell-free DNA (cfDNA) shed by tumor cells into the bloodstream. StemExpress has been supporting the recruitment of donors and collection of blood samples for this project since 2010. Grail has raised $1.1 billion, a sum that puts it among the top three most heavily funded private biotech companies (News Article).
Perkins Elmer, Inc.
StemExpress has supported Perkins Elmer in their development of the DELFIA®and AutoDELFIA®PlGF 1-2-3 kit (Product Info.), both of which have passed clinical approval by the FDA. The kits determine the levels of Placental Growth Factor (PlGF) in maternal serum, which can aid in the detection of women who are prone to the development of pre-eclampsia and can also be used in the detection of Down’s syndrome (Product Info.).
Cell-FREE DNA BCT® Blood Tubes (Product Info.) are blood collection tubes which stabilize nucleated blood cells. The unique preservative prevents the release of genomic DNA, allowing isolation of high-quality cfDNA. StemExpress was one of the main donor recruitment and collection sites for these tubes.
Stryker (Company Info.) is a world leader in medical device and equipment manufacturers in the areas of orthopedics, medical and surgical, and neurotechnology, and has relied on StemExpress for clinical device development.
SynGen, Inc. (Company Info.) develops advanced cell separation tools and accessories, applying innovative design to aid regenerative medicine workflows. From the beginning, StemExpress has been their R&D and clinical partner in the development of equipment and blood collection devices. SynGen has since been acquired by ThermoGenesis, also a StemExpress client.
Cesca Therapeutics, Inc.
Cesca Clinical (Company Info.) is their therapeutics division, which leverages their proprietary cellular processing technology platform to develop safe and efficacious point-of-care therapies. StemExpress has been a partner in their R&D and clinical device development.
StemExpress was an end-to-end business partner with Biomatrica in the development of LBgard® Blood Tubes which are designed for the recovery of cfDNA and cancer tumor cells (CTCs) from liquid biopsies (Product Info.).